PuSH - Publikationsserver des Helmholtz Zentrums München

Müller, T.D. ; Adriaenssens, A.* ; Ahrén, B.* ; Blüher, M. ; Birkenfeld, A.L. ; Campbell, J.E.* ; Coghlan, M.P.* ; D'Alessio, D.* ; Deacon, C.F.* ; DelPrato, S.* ; Douros, J.D.* ; Drucker, D.J.* ; Figueredo Burgos, N.S.* ; Flatt, P.R.* ; Finan, B.* ; Gimeno, R.E.* ; Gribble, F.M.* ; Hayes, M.R.* ; Hölscher, C.* ; Holst, J.J.* ; Knerr, P.J.* ; Knop, F.K.* ; Kusminski, C.M.* ; Liskiewicz, A. ; Mabilleau, G.* ; Mowery, S.A.* ; Nauck, M.A.* ; Novikoff, A. ; Reimann, F.* ; Roberts, A.G.* ; Rosenkilde, M.M.* ; Samms, R.J.* ; Scherer, P.E.* ; Seeley, R.J.* ; Sloop, K.W.* ; Wolfrum, C.* ; Wootten, D.* ; DiMarchi, R.D.* ; Tschöp, M.H.

Glucose-dependent insulinotropic polypeptide (GIP).

Mol. Metab. 95:102118 (2025)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
BACKGROUND: Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in the maintenance of glucose tolerance in healthy humans. Until recently GIP had not been developed as a therapeutic and thus has been overshadowed by the other incretin, glucagon-like peptide 1 (GLP-1), which is the basis for several successful drugs to treat diabetes and obesity. However, there has been a rekindling of interest in GIP biology in recent years, in great part due to pharmacology demonstrating that both GIPR agonism and antagonism may be beneficial in treating obesity and diabetes. This apparent paradox has reinvigorated the field, led to new lines of investigation, and deeper understanding of GIP. SCOPE OF REVIEW: In this review, we provide a detailed overview on the multifaceted nature of GIP biology and discuss the therapeutic implications of GIPR signal modification on various diseases. MAJOR CONCLUSIONS: Following its classification as an incretin hormone, GIP has emerged as a pleiotropic hormone with a variety of metabolic effects outside the endocrine pancreas. The numerous beneficial effects of GIPR signal modification render the peptide an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, drug-induced nausea and both bone and neurodegenerative disorders.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Diabetes ; Gip ; Glp-1 ; Incretin ; Insulin ; Obesity
ISSN (print) / ISBN 2212-8778
e-ISSN 2212-8778
Zeitschrift Molecular Metabolism
Quellenangaben Band: 95, Heft: , Seiten: , Artikelnummer: 102118 Supplement: ,
Verlag Elsevier
Verlagsort Amsterdam
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
Institute of Diabetes Research and Metabolic Diseases (IDM)
Förderungen EFSD/Novo Nordisk Foun-dation Future Leaders Award
Boehringer Ingelheim
Pfizer
Eli Lilly Co.
Novo Nordisk Foundation
EFSD/Lilly European Diabetes Research Programme
NHMRC Leadership Fellow
Diabetes UK
Northern Ireland HPSS and Invest Northern Ireland
Nordisk Chair in incretin biology and a Sinai Health Novo Nordisk Fund in regulatory peptides